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Objectives This study sought to perform a weighted meta-analysis of the complication risk during
chronic total occlusion (CTO) percutaneous coronary intervention (PCI).
Background The safety proﬁle of CTO PCI has received limited study.
Methods We conducted a meta-analysis of 65 studies published between 2000 and 2011 reporting
procedural complications of CTO PCI. Data on the frequency of death, emergent coronary artery by-
pass graft surgery, stroke, myocardial infarction, perforation, tamponade, stent thrombosis, major
vascular or bleeding events, contrast nephropathy, and radiation skin injury were collected.
Results A total of 65 studies with 18,061 patients and 18,941 target CTO vessels were included.
Pooled estimates of outcomes were as follows: angiographic success 77% (95% conﬁdence interval
[CI]: 74.3% to 79.6%); death 0.2% (95% CI: 0.1% to 0.3%); emergent coronary artery bypass graft sur-
gery 0.1% (95% CI: 0.0% to 0.2%); stroke 0.01% (95% CI: 0.0% to 0.1%); myocardial infarction 2.5%
(95% CI: 1.9% to 3.0%); Q-wave myocardial infarction 0.2% (95% CI: 0.1% to 0.3%); coronary perfora-
tion 2.9% (95% CI: 2.2% to 3.6%); tamponade 0.3% (95% CI: 0.2% to 0.5%); and contrast nephropa-
thy 3.8% (95% CI: 2.4% to 5.3%). Compared with successful procedures, unsuccessful procedures had
higher rates of death (0.42% vs. 1.54%, p  0.0001), perforation (3.65% vs. 10.70%, p  0.0001), and
tamponade (0% vs. 1.65%, p  0.0001). Among 886 lesions treated with the retrograde approach,
success rate was 79.8% with no deaths and low rates of emergent coronary artery bypass graft sur-
gery (0.17%) and tamponade (1.2%).
Conclusions CTO PCI carries low risk for procedural complications despite high success rates. (J Am Coll
Cardiol Intv 2013;6:128–36) © 2013 by the American College of Cardiology Foundation
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129Chronic total occlusions (CTO) are encountered in 15% to
30% of patients undergoing coronary angiography (1).
Compared with failed CTO PCI, successful CTO percu-
taneous coronary intervention (PCI) has been associated
with improvement in angina, left ventricular function,
and increased survival (2,3). Despite these benefits, CTO
PCI is performed infrequently (2), likely due to histori-
cally low procedural success rates, technical complexity,
See page 137
high equipment use, and the potential for major periproce-
dural complications (4). In the past decade, new devices,
increased operator experience, and new crossing techniques,
such as the retrograde approach have helped overcome
technical complexities leading to improved procedural suc-
cess rates (5). However, there remain concerns that CTO
PCI may be associated with high risk for procedural
complications. Thus, we performed a meta-analysis of
published CTO PCI series to better characterize the inci-
dence of procedural complications.
Methods
Search strategy and eligibility criteria. We performed a com-
prehensive search of the PubMed and Cochrane Library data-
bases for manuscripts on coronary CTO. Bibliographies of
the retrieved studies were searched by hand for other
relevant studies. Human studies in English published be-
tween the years 2000 and 2011 were included if they
reported any of the following procedural complications of
CTO PCI: death; emergent or urgent coronary artery
bypass graft (CABG); stroke; myocardial infarction (MI);
perforation; tamponade; stent thrombosis; major vascular
complications; major bleeding; contrast nephropathy; and
radiation skin injury. Major adverse cardiovascular events
were defined as the composite of death, emergent CABG,
stroke, and MI. Review articles, letters to the editor, case
reports, and studies in which procedural complications
could not be accurately assessed from the published manu-
script were excluded. Series of balloon uncrossable CTO or
anomalous coronaries were also excluded. Series consisting
exclusively of successful CTO PCI procedures were ex-
cluded from the overall study; however, these were included
in a separate analysis comparing procedural complications of
successful versus unsuccessful CTO PCI procedures. A list
of the included studies is shown in Online Table 1. Because
there are no validated scales for assessment of quality of
observational series (6), the proportion of studies reporting
each individual outcome was used as a measure of robust-
ness (Table 1) (7). There was robust assessment of angio-
graphic success, death, emergent CABG, stroke, MI, cor-
onary perforation, and tamponade.Data extraction. Data from included studies were extracted
y 2 authors (V.P. and E.B.) and controversies were
eviewed by both; in case of disagreement, a third reviewer
S.B.) was used to reach a consensus. Extracted data
ncluded the total number of patients and lesions, age, sex,
istory of prior CABG, frequency and outcomes of the
etrograde approach, target vessel, angiographic success, and
ccurrence of complications. The country and institute of
rigin, author, and enrollment period were reviewed to
dentify and exclude duplicate publications from the same
ohort.
Statistical analysis. The frequency of each evaluated out-
ome was abstracted from each study and presented as
inimum, maximum, and cumulative rates. To assess het-
rogeneity across trials, we used the Cochrane Q statistic (a
value 0.1 was considered significant) and I2 statistic
(25%, 50%, and 75% correlate with low, moderate, and high
heterogeneity, respectively) for each outcome. Due to its
conservative or “worst-case scenario” estimates, a random-
effects model as described by DerSimonian and Laird (8)
was used to obtain a summary
estimate and 95% confidence in-
tervals (CI). However, the cu-
mulative proportion and corre-
sponding confidence intervals
are presented in Online Tables 2
and 3. Data collection, study
selection, processing of the data,
and reporting of the results were
performed according to accepted
principles related to systematic
review and meta-analysis (7,9–
11). Publication bias for angio-
graphic success and death rates
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CI  confidence interval
CTO  chronic total
occlusion
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
Table 1. Proportion of Studies Reporting Success and Various
Complication Rates of CTO PCI
Variable
Proportion of Studies
Reporting Outcome
Angiographic success 64/65 (98.5)
Death 65/65 (100)
Emergent coronary artery bypass graft 65/65 (100)
Stroke 65/65 (100)
Myocardial infarction 55/65 (84.6)
Q-wave myocardial infarction 46/65 (70.8)
Coronary perforation, per lesion 49/65 (75.4)
Tamponade 54/65 (82.8)
Acute stent thrombosis 25/65 (38.5)
Vascular complication 15/65 (23.1)
Major bleed 13/65 (20.0)
Contrast nephropathy 13/65 (20.0)
Radiation injury 7/65 (10.8)Values are n/N (%).
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 2 , 2 0 1 3
F E B R U A R Y 2 0 1 3 : 1 2 8 – 3 6
Patel et al.
Meta-Analysis of Complications of CTO PCI
130were estimated visually by funnel plots and are presented in
Online Figures 1 and 2. Proportions were compared using the
chi-square test, and p  0.05 was considered statistically
significant. A logistic regression model using study publication
year was developed to evaluate for temporal trends in angio-
graphic success rates and major complications. Statistical anal-
yses were performed using Stata (version 11, StataCorp,
College Station, Texas).
Results
Search results. Of 640 studies retrieved through electronic
and manual search, 65 studies met the inclusion criteria and
were included in the final pooled analysis (Fig. 1). A full
listing of all 65 articles is provided in Online Table 1. Table 1
shows the number of articles that reported success and
various complication rates of CTO PCI. The 65 published
studies reported outcomes on 18,061 patients who under-
went CTO PCI of 18,941 target vessels (Table 2). Mean
age of the cohort was 62.4 years, most patients (81.9%) were
men, and 15.2% had prior CABG. The most common
target vessel was the right coronary artery followed by the
left anterior descending and the left circumflex arteries.
Incidence of angiographic success and procedural complica-
tions. The overall angiographic success rate ranged between
41.2% and 100% with a pooled estimate of 77% (95% CI:
74.3% to 79.6%) (Table 3). The reported major adverse
Records Ide
Abstracts aer non-human and non
English studies excluded 
(n = 552) 
Full text arcles 
assessed for eligibility 
(n = 328) 
Studies included 
in meta-analysis 
(n = 65) 
Records Idenﬁed Through Hand 
Searching 
(n = 1) 
Figure 1. Flow Diagram of the Literature Search and Study Selection
CTO  chronic total occlusion; PCI  percutaneous coronary intervention.cardiovascular events rate in 15,718 patients ranged from0% to 19.4% with a pooled estimate of 3.1% (95% CI: 2.4%
to 3.7%). Most of the major adverse cardiovascular events
consisted of MI, with a pooled estimate rate of 2.5%. There
were 77 deaths in the cohort with a reported range from 0%
to 3.6%, yielding a pooled estimate of 0.2%. Emergent
CABG, stroke, and radiation injury were the least common
complications with rates of 0.1%, 0.01%, and 0.01%,
respectively, in pooled analyses. The most commonly ob-
served complications were perforation (2.9%, 95% CI: 2.2%
to 3.6%) and contrast nephropathy (3.8%, 95% CI: 2.4% to
5.3%). Inspection of funnel plots demonstrated no evidence
Through Database 
hing 
639) 
Non-Human (n = 41) 
Non-English (n=47) 
Records Exluded (n = 224) 
CTO PCI Complicaons Not Reported - 159 
Not Coronary CTO – 49 
Not Adult – 2 
Not PCI – 13 
Anomalous Coronary – 1 
Duplicate – 2 
Records Exluded (n = 263) 
CTO PCI Complicaons Not Reported – 174 
Subset of a Larger Series - 7 
Duplicate – 2 
Balloon Impassable CTO – 3 
*Successful Type Procedure – 12 
Incomplete Complicaon Reporng – 4 
Case Reports – 25 
Not PCI – 1 
Not Coronary CTO - 5 
*Included for successful vs unsuccessful analysis 
Table 2. Patient Demographics and CTO Target Vessel
Patients 18,061
Lesions 18,941
Age, yrs 62.4 3.1
Male 14,660/17,893 (81.9)
Previous CABG 2,171/14,244 (15.2)
Retrograde approach 1,440/5,449 (26.4)
CTO target vessel 17,942
Left main 59 (0.3)
Left anterior descending artery 6,126 (34.1)
Circumﬂex 3,818 (21.3)
Right coronary artery 7,486 (41.7)
Bypass graft 110 (0.6)
Other 343 (1.9)
Values are mean SD, n/N (%) or n (%).nﬁed 
Searc
(n = 
-CABG coronary artery bypass graft surgery; CTO chronic total occlusion.
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131for publication bias for procedural success but a possibility
for publication bias for death (Online Figs. 1 and 2).
Successful versus unsuccessful procedures and use of the
retrograde approach. Compared with successful proce-
dures, unsuccessful procedures had significantly higher rates
of death (1.5% vs. 0.4%), stroke (0.4% vs. 0.07%), perforation
(10.7% vs. 3.7%), and tamponade (1.7% vs. 0%) (Table 4).
However, the frequency of emergent CABG, MI, Q-wave
MI, and contrast nephropathy was similar between success-
ful and unsuccessful procedures.
Among 884 patients undergoing CTO PCI of 886
lesions using a retrograde approach, angiographic success
was reported from 55.6% to 100% with a pooled estimate
rate of 83.8% (95% CI: 76.9% to 90.7%) (Table 5). The
most commonly observed complications in patients who
received a retrograde CTO PCI approach were MI (1.8%;
95% CI: 1.5% to 4.1%), perforation (3.2%; 95% CI: 0.8% to
5.5%), and contrast nephropathy (1.2%, 95% CI: 0% to
Table 3. Frequency of Angiographic Success and Complications in CTO PC
Outcome
Pooled Estimate
Rate, % 95% CI
Repo
Mi
Angiographic success 77.0 74.3–79.6 41
MACE 3.1 2.4–3.7
Death 0.2 0.1–0.3 0
Emergent CABG 0.1 0–0.2
Stroke 0.01 0–0.1
Myocardial infarction 2.5 1.9–3.0
Q-wave myocardial infarction 0.2 0.1–0.3
Coronary perforation, per lesion 2.9 2.2–3.6
Tamponade 0.3 0.2–0.5
Acute stent thrombosis 0.3 0.1–0.5
Vascular complication 0.6 0.3–0.9
Major bleed 0.4 0–0.7
Contrast nephropathy 3.8 2.4–5.3 2
Radiation skin injury 0.01 0–0.1
CI confidence interval; MACEmajor adverse cardiac events (composite of death, emergency C
in Table 2.
Table 4. Incidence of Procedural Complications in Su
Outcome Successful
MACE 84 (3.7)
Death 19 (0.4)
Emergent CABG 1 (0.03)
Stroke 3 (0.07)
Myocardial infarction 106 (2.8)
Q-wave myocardial infarction 10 (0.3)
Coronary perforation, per lesion 67 (3.7)
Tamponade 0 (0)
Vascular complication 33 (1.7)
Contrast nephropathy 18 (5.0)
Values are n (%).Abbreviations as in Tables 2 and 3.2.7%). Major complications, such as death, emergent
CABG, and stroke were rare, with each occurring in 0.1%
of patients.
Temporal trends. To evaluate changes over time, studies were
divided into 4 groups based on publication year (Table 6).
Most studies were published within the last 6 years. The
pooled angiographic success rate increased in each succes-
sive quartile from 68.2% in studies published between the
years 2000 and 2002 to 79.4% in studies published between
2009 and 2011 (Fig. 3). With each successive year, the rate
of angiographic success increased significantly (odds ratio
[OR]: 1.06, 95% CI: 1.05 to 1.07). There was also signif-
icant decrease in the rate of major complications over time,
with studies published between 2000 and 2002 reporting a
rate of 1.6%, which decreased to 0.5% for studies published
between 2009 and 2011 (Fig. 3). For each successive year,
the rate of major complications decreased significantly (OR:
0.93, 95% CI: 0.89 to 0.97).
ate,
%
Cumulative Rate,
n/N I2, % Cochran’s Q
p Value
Heterogeneity
.0 14,414/18,828 94.4 1,120.6 0.0001
500/15,718 79.4 262.0 0.0001
77/18,061 0.0 39.3 0.994
52/18,061 0.0 29.7 1.000
11/18,061 0.0 6.0 1.000
490/15,718 77.3 238.4 0.0001
61/13,353 0.0 38.2 0.752
418/12,254 79 228.6 0.0001
74/13,103 0.0 27.9 0.998
51/9,338 31.9 35.3 0.065
66/7,308 35.7 21.8 0.084
32/5,108 54.6 26.5 0.009
165/4,796 89.5 114.3 0.0001
3/2,857 0.0 2.18 0.902
oke, and myocardial infarction); PCI percutaneous coronary intervention; other abbreviations as
ful Versus Unsuccessful CTO PCI
Unsuccessful Chi-Square p Value
14 (4.3) 0.2 0.68
17 (1.5) 15.1 0.0001
1 (0.17) 0.1 0.74
4 (0.4) 4.1 0.04
25 (3.0) 0.03 0.87
6 (0.5) 1.3 0.26
55 (10.7) 39.2 0.0001
7 (1.7) 16.8 0.0001
6 (0.9) 1.7 0.20
5 (4.6) 0.03 0.86I
rted R
n–Max
.2–100
0–19.4
.0–3.6
0–2.3
0–0.7
0–19.4
0–2.6
0–11.9
0–4.7
0–2.0
0–2.8
0–3.7
.4–18.1
0–11.1
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132CTO duration deﬁnition. The 44 studies that had a strict
CTO duration requirement of 3 months were compared
with the remaining 21 studies to assess the effect of CTO
duration on angiographic success and major procedural
complications. There was a nonsignificant trend toward
more recent publication in studies that had a strict CTO
duration criteria of 3 months versus those without (me-
dian year of publication 2009 vs. 2008, p  0.07). Com-
pared with studies that included CTO duration3 months,
studies that included only CTO duration 3 months
reported higher angiographic success rates without signifi-
cant differences in the rate of major procedural complica-
tions (Table 7).
Operator volume. Although operator volume could not be
irectly assessed, a surrogate defined by study size greater
han the median was used to assess the impact of CTO case
olume on angiographic success and major procedural com-
lications. The median study size was 134 patients. There
as no difference in the angiographic success rate (76.2% vs.
6.6%, p  0.7) or major complication rate (0.2% vs. 0.8%,
 0.06) between smaller and larger studies.
iscussion
Our meta-analysis is the first to evaluate the pooled angio-
graphic success and procedural complication rates of CTO
Table 5. Incidence of Angiographic Success and Procedural Complications
Outcome
Pooled Estimate
Rate, % 95% CI
Repo
Mi
Angiographic success 83.8 76.9–90.7 5
MACE 3.1 1.7–4.4
Death 0.1 0–0.7
Emergent CABG 0.1 0–0.6
Stroke 0.1 0–0.6
Myocardial infarction 2.8 1.5–4.1
Q-wave myocardial infarction 0.2 0–0.9
Coronary perforation, per lesion 3.2 0.8–5.5
Tamponade 0.5 0–1.2
Acute stent thrombosis 0.1 0–0.8
Contrast nephropathy 1.2 0–2.7
Radiation injury 0.01 0–0.8
Abbreviations as in Tables 2 and 3.
Table 6. Temporal Trends in Cumulative Angiographic Success Rates and
Publication Year Studies Patients Lesions
Angiographic Success,
n (%)
2000–2002 6 2,766 2,833 1,933 (68.2)
2003–2005 7 1,607 1,677 1,149 (73.5)‡
2006–2008 20 5,331 5,770 4,457 (77.2)
2009–2011 32 8,357 8,661 6,875 (79.4)*Compared to prior 3 years. †Combined death, emergent coronary artery bypass graft, and stroke. ‡Out oPCI. The main findings are that CTO PCI: 1) is performed
with increasing success rates; and 2) carries low risk of major
complications; 3) compared to successful CTO PCI, unsuc-
cessful CTO PCI is associated with significantly higher
rates of death, stroke, coronary perforation, and tamponade;
and 4) retrograde CTO PCI is associated with low proce-
dural complication risk.
Success rate. The pooled angiographic success rate in this
nalysis is 77% and has increased over time (Fig. 3). This is
ikely the result of improved equipment and CTO PCI
echniques. The advent and subsequent widespread use of
tents in the late 1990s to early 2000s was the first major
tep toward a significant increase in CTO PCI success rates
rom approximately 50% in the pre-stent era to 70%
fterward (12). The development of new crossing and
e-entry devices, microcatheters, and guidewires contributed
o further increases in the success rates in recent years.
inally, the introduction of new CTO PCI techniques and
rossing strategies, such as the use of contralateral injec-
ions, dissection/re-entry techniques, and the retrograde
pproach coupled with dedicated high volume CTO PCI
perators likely accounts for the higher success rates in
odern CTO PCI demonstrated in this analysis (13–15).
We used study size as a surrogate for operator volume to
nderstand the effect of operator volume on angiographic
trograde CTO PCI
ate,
%
Cumulative Rate,
n/N I2, % Cochran’s Q
p Value
Heterogeneity
0 707/886 84.9 72.7 0.0001
31/853 0.0 6.41 0.780
1/884 0.0 0.4 1.000
1/884 0.0 0.5 1.000
1/884 0.0 0.5 1.000
28/853 0.0 5.6 0.848
2/803 0.0 0.6 1.000
31/828 62.1 21.1 0.007
9/817 0.0 4.0 0.912
1/428 0.0 0.5 0.974
.1 6/378 0.0 1.4 0.701
.1 1/293 0.0 0.8 0.662
Procedural Complication Rates by Study Publication Year
hi-Square p Value*
Major Complications,
n (%)† Chi-Square p Value*
45 (1.6)
0.03 0.8691 9 (0.6) 8.6 0.0033
52.7 0.0001 43 (0.8) 0.7 0.4012
9.2 0.0024 43 (0.5) 4.0 0.0457in Re
rted R
n–Max
5.6–10
0–7.1
0–0.4
0–0.6
0–0.6
0–7.1
0–0.6
0–14
0–4.5
0–1.2
0–11
0–11Major
Cf 1,564 lesions.
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133success rates. Although we did not find a difference in
angiographic success and complication rates between
smaller and larger studies, study size is likely a poor
surrogate for operator volume. Indeed, several investigators
who may be traditionally considered “high-volume” CTO
operators have also published small-size studies.
Contrary to what might be expected, angiographic suc-
cess rates were higher in studies that used a strict definition
of CTO duration greater than 3 months as compared to
those allowing CTO of shorter duration. A number of
possible explanations may account for these findings. First,
studies that allowed shorter duration occlusions may still
have included a significant number of patients with occlu-
sions of longer duration. Second, studies that required a
CTO duration of 3 months tended to be published later
0.0%
0.5%
1.0%
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2.0%
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Figure 2. Pooled Complication Rates
Pooled complication rates of chronic total occlusion percutaneous coronary in
MACE  major adverse cardiac events; MI  myocardial infarction; QWMI  Q
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Figure 3. Temporal Trends in Cumulative Angiographic Success Rates
and Major Procedural Complication Rates
Temporal trends in cumulative angiographic success rates and major proce-
dural complication rates, presenting according to the study publication
year.cand thus may be more reflective of modern techniques that
have resulted in higher rates of angiographic success. Fi-
nally, determining the duration of occlusion is an inexact
science when serial angiograms are unavailable and relies
largely on clinical history; it is possible that some patients
deemed to have occlusions 3 months in age may actually
have had occlusions that were 3 months in age.
Death, emergent CABG, and stroke. The most serious po-
ential complications of any PCI are death, need for
mergency CABG, and stroke. Such complications are of
articular concern in the context of CTO PCI, as most of
hese patients are presenting electively for stable angina (5).
he rates of death, emergent CABG, and stroke in 1 of the
argest previously published series of 2,007 patients under-
oing CTO PCI were 1.3%, 0.7%, and 0.01%, respectively
16). On the other end of the spectrum, a study of 1,463
atients undergoing elective PCI from April 2003 to 2006
eported 0.1% mortality (17). Our analysis falls between
hese studies, demonstrating low rates of each of the major
omplications in pooled estimates. Ultimately, the data
uggest that the risk of major complications from CTO PCI
s likely slightly higher than that of routine elective PCI, but
ower than the common perception.
Myocardial infarction. Periprocedural myocardial infarction
s among the most common complications of CTO PCI.
owever, most MI are non–Q-wave MI diagnosed by
symptomatic cardiac biomarker elevation. The MI rates in
ur study ranged widely from 0% to 19.4%, likely reflecting
ignificant variability in the frequency of systematic cardiac
iomarker measurement after PCI. This is consistent with
reviously published data from the National Cardiovascular
ata Registry, in which a median of only 7% of patients had
tions. CABG  coronary artery bypass graft; CN  contrast nephropathy;
myocardial infarction.tervenardiac biomarker measurements after PCI (18). Whereas
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134cardiac biomarker elevation after routine PCI is associated
with higher immediate and long-term mortality, the clinical
and therapeutic implications of these events remain unclear
(19). Studies that report results of systematic cardiac bio-
marker measurements following CTO PCI are needed.
Coronary perforation and tamponade. Coronary perforation
s among the most feared complications of CTO PCI, due
o the risk of tamponade. CTO PCI carries increased risk of
erforation due to routine use of stiff and polymer-jacketed
uidewires and frequent uncertainty about the vessel course.
he incidence of coronary perforation in non-CTO PCI is
pproximately 0.19% and occurs more commonly in heavily
alcified tortuous vessels using hydrophilic wires and athero-
blative devices (20–22). Most of these cases do not result
n tamponade and can be managed conservatively (20).
imilarly, in our analysis, coronary artery perforation oc-
urred in 2.9% of patients; however, only 0.3% of patients
eveloped tamponade. Hence, most of the perforations were
elf-limited. Perforation can occur in a major vessel (usually
fter balloon or stent placement) or at a distal vessel branch
r a collateral vessel (23). Despite its relatively rare occur-
ence, it is important for every CTO PCI program to have
he necessary equipment for managing perforations, such as
overed stents and coils (23).
Contrast nephropathy. Contrast nephropathy is a common
PCI complication, occurring in 10% to 15% of all PCI
patients (24,25), and has been linked with adverse clinical
outcomes, including prolonged hospital stay, progression of
chronic kidney disease, MI, and death (26,27). Given that
higher contrast volume is associated with higher risk for
contrast nephropathy, it is not surprising that contrast
nephropathy is among the most common complications of
CTO PCI (28). Studies included in our analysis reported
rates of contrast nephropathy that varied from 2.4% to
18.1%, with a pooled estimate rate of 3.4%. However, this
is likely an underestimate of the true incidence of contrast
nephropathy, as only 20% of studies reported the data on
contrast nephropathy and even those studies likely did not
perform systematic serial assessment of renal function. As
Table 7. Incidence of Angiographic Success and Major Procedural Complic
Outcome
CTO Duration
> 3 Months,
n/N (%)
CTO Duration
< 3 Months or No
Specific Criteria,
n/N (%) Chi-Square
Angiographic success 9,889/12,345 (80.1) 4,525/6,483 (69.8) 251.0
Major complications* 80/11,650 (0.7) 60/6,411 (0.9) 3.0
Death 42/11,650 (0.4) 35/6,411 (0.5) 2.9
Emergent CABG 29/11,650 (0.2) 23/6,411 (0.4) 1.4
Stroke 9/11,650 (0.8) 2/6,411 (0.1) 0.8
*Combined death, emergent CABG, stroke.
Abbreviations as in Table 2.CTO PCI may require administration of a large amount of scontrast, prophylactic measures, such as hydration, are
important to minimize the risk for contrast nephropathy.
Major vascular and bleeding complications. Bleeding is a
ommon noncardiac complication in patients undergoing
CI and is associated with a poor prognosis (29). Presenting
ith acute coronary syndrome, cardiogenic shock, female
ex, advanced age (85 years), and renal dysfunction are all
redictive of increased bleeding risk (30). In addition to
hese established risk factors, CTO PCI has the potential to
arry increased risk for bleeding due to use of large caliber
heaths and high frequency of dual (or occasionally triple)
rterial access (31). However, use of intensive anticoagula-
ion and antiplatelet regimens (such as glycoprotein IIb/IIIa
nhibitors) is generally limited in CTO PCI due to the
ossibility of coronary perforation, which potentially lessens
he risk for vascular access bleeding. Moreover, men have a
ower risk of access complications than women do, and men
omposed most of the CTO PCI patients in our study.
ndeed, in the present study, the pooled rate of major
leeding was 0.4%, which could, however, be underreported
only 20% of studies reported major bleeding complications
nd the definition of major bleeding varied from study to
tudy).
Radiation skin injury. Radiation skin injury is of particular
oncern in patients undergoing CTO PCI, as long fluoros-
opy and cine-angiography exposure may be required to
ross and treat the lesion. As a result, careful attention to the
adiation dose administered is recommended during the
ase with abortion of the procedure if crossing has not
ccurred after 8 to 10 Gy of air kerma exposure. Radiation
kin injury was the least studied CTO complication in the
resent meta-analysis with only 11% of studies reporting on
ts occurrence and only 3 reported cases among 2,857
atients. Similar under-reporting of radiation exposure is
rue for most PCI studies (32). In part, this systematic
nder-reporting of radiation skin injury may be because this
omplication may not become apparent until weeks or
onths after the procedure. Regardless, studies, including
Stratified by CTO Duration and Study Size
Value
Study Size
< Median, n/N (%)
Study Size
> Median n/N (%) Chi-Square p Value
.0001 1,471/1,930 (76.2) 12,943/16,897 (76.6) 0.1 0.7288
.0821 8/1,997 (0.2) 132/16,064 (0.8) 3.6 0.0590
.0871 3/1,997 (0.2) 74/16,064 (0.5) 3.3 0.0679
.2408 5/1,997 (0.3) 47/16,064 (0.3) 0.1 0.9179
.3760 0/1,997 (0.0) 11/16,064 (0.1) 0.5 0.4909ations
p
0
0
0
0
0ystematic screening for radiation skin injury weeks and
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135months after PCI are needed to better define its incidence
and implications.
Study limitations. First, only complication rates that were
learly reported in each article were included. Although this
s unlikely to affect major complications, such as death or
mergent CABG, less serious complications, such as MI,
ascular complications, or bleeding, could be either under-
r over-reported (as some investigators may not report an
utcome because it did not occur). Second, systematic
valuation for certain complications, such as MI, contrast
ephropathy, and radiation skin injury, was not performed.
hird, publication bias is always possible in meta-analyses.
isual assessment of the funnel plot for angiographic
uccess rates appeared symmetrical and unbiased; however,
he funnel plot for death suggested that publication bias was
ossible. Publication bias may have also affected other
eriprocedural complications of CTO PCI, leading to
nderestimation of other complication rates. Fourth, many
f the published studies were from dedicated high CTO
CI volume centers and expert operators; thus, these event
ates may not reflect “real-world” event rates. However, this
ffect could be mitigated, at least in part, in our study by
nclusion of multiple small series from low-volume centers
orldwide. Fifth, whereas a patient-level meta-analysis
ould be ideal, this is unlikely to ever be performed and the
resent study-level pooled analysis provides the best cur-
ently available data on the frequency of CTO PCI com-
lications. Sixth, the definitions for some of the complica-
ions may have varied across studies, highlighting the
mportance of defining and using universally acceptable
efinitions for future studies.
onclusions
Our meta-analysis demonstrates that CTO PCI is currently
performed with high and improving success and low and
decreasing complication rates, suggesting that CTO PCI
carries a favorable risk/benefit ratio and supporting its
increasing use for the treatment of this complex lesion and
patient group.
Reprint requests and correspondence: Dr. Emmanouil S. Brila-
kis, Dallas Veterans Administration Medical Center (111A), 4500
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